Valid regimens for cancer prevention must consider the targets of multiple cell types that are targetable for angiogenic factors, such as platelet-derived growth factor (PDGF), PDGF receptor (PDGFR), angiopoietin 1/2 (Ang1/2), ECs, and EPCs (Rajabi and Mousa, 2017). Here, ANGPT1 is linked to cancer.